Condition
Idiopathic CD4 Lymphopenia
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Belimumab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 1/2 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT05600920Phase 1/2RecruitingPrimary
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
NCT04097561Phase 1RecruitingPrimary
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Showing all 2 trials
Research Network
Common Treatments
- Belimumab1
- Recombinant Human Interleukin Il 7hyfc1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)2
- NeoImmuneTech1
Top Investigators
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)